A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

Inclusion criteria

• ≥18 years of age at time of informed consent.
• Diagnosis of autoimmune diseases according to the corresponding disease classification criteria.
• Inadequate response to SoCs or relapsed after the treatment.
• Patients were on a stable dose of SoCs for at least 4 weeks prior to enrollment.
• Sufficient organ function.

Exclusion criteria

• Active infection, including tuberculosis, active or relapsed peptic ulcer, etc.
• Severe hypogammaglobulinemia or IgA deficiency.
• Active hepatitis or with a history of severe liver disease.
• History of rapid allergic reactions, eczema or asthma that cannot be controlled by topical corticosteroids.
• Severe cardiovascular diseases.
• History of cancer within past 5 years.
• Have other serious medical conditions.
• Received any of B cell targeted therapies and biologic therapies within the defined time window.
• History of severe allergies or known allergies to any active or inactive component of the study drug(s).
• A history of organ transplantation, bone marrow transplantation or hematopoietic stem cell transplantation.